Celgene

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Anokion is a biotechnology company focused on antigen-specific immune tolerance to reduce immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. A spin-off from EPFL, it uses a platform technology that can be applied to many proteins across multiple clinical indications, including autoimmune conditions such as celiac disease, multiple sclerosis, and diabetes. The company is based in Ecublens, Switzerland.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Aitia is a leader in the application of Causal AI and Digital Twins focused on advancing drug discovery and development. The company utilizes machine learning and the convergence of multi-omic patient data to create Digital Twins that replicate the biological mechanisms of diseases. This innovative approach is particularly impactful in areas such as oncology, neurodegenerative disorders, and immunology. Aitia's Gemini Digital Twins are currently employed to identify novel therapies and expedite research and development in various conditions, including multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with additional projects underway. The company collaborates with several prominent pharmaceutical firms, academic institutions, medical societies, and patient advocacy groups worldwide, thereby enhancing the potential for breakthroughs in medicine.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Biond Biologics Ltd is a clinical-stage biopharmaceutical company based in Misgav, Israel, specializing in drug discovery and development for immuno-oncology and autoimmune diseases. Founded in 2016, Biond is focused on creating innovative therapies that address significant unmet medical needs. The company engages in extensive research to uncover immunoregulatory pathways and investigates immune checkpoints and immune-evasion mechanisms. Biond has developed a novel platform that targets intracellular immune factors, enabling the delivery of therapies for conditions previously considered undruggable. Through its commitment to high-quality science and innovation, Biond aims to advance the field of cancer immunotherapy and improve treatment options for patients.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Skyhawk Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapeutics that aim to correct RNA expression. The company's proprietary technology facilitates the rational design of these small molecules to target specific binding pocket regions on RNA, employing both sequence and structural specificity at critical moments during the RNA splicing process. This innovative approach allows for the targeting of diseases associated with RNA mis-splicing, particularly those characterized by exon skipping. Skyhawk Therapeutics is committed to developing treatments for various conditions, including cancer, neurological diseases, and rare disorders. Founded in 2015 and headquartered in Waltham, Massachusetts, the company has evolved from its initial identity as Rare Genetix, Inc., adopting its current name in May 2018.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell-based immunotherapies for cancer treatment. Utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies, Juno engineers T cells to target and eliminate cancer cells. The company's product pipeline includes several promising candidates, such as JCAR017, in Phase I/II trials for relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, as well as JCAR018 for pediatric patients with CD22-positive cancers. Other candidates target various malignancies, including neuroblastoma, lung cancer, ovarian cancer, and glioblastoma. Juno collaborates with leading cancer research institutions to advance its therapies and was founded in 2013, headquartered in Seattle, Washington. In 2018, Juno became a subsidiary of Bristol-Myers Squibb Company.

Impact Biomedicines, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and other cancers. Founded in 2016 and headquartered in San Diego, California, the company is primarily centered on its lead product, fedratinib, a potent and selective oral small molecule JAK2 kinase inhibitor. Fedratinib is being developed for the treatment of myelofibrosis and polycythemia vera, with additional potential applications in acute myeloid leukemia and colorectal cancer. As of February 2018, Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally delivered small-molecule therapies for oncology and inflammatory diseases. It uses a proprietary discovery and development engine to create highly selective compounds that modulate immune responses. The company's lead oncology candidate, FLX475, targets the C-C motif chemokine receptor 4 and is in a Phase 1/2 program as monotherapy and in combination with pembrolizumab. The lead inflammation candidate, RPT193, is designed to selectively inhibit migration of type 2 T helper cells into inflamed tissues. Additional targets such as general control nonderepressible 2 and hematopoietic progenitor kinase 1 are in discovery. Founded in 2015 and headquartered in South San Francisco, the company aims to address unmet medical needs in cancer and inflammatory diseases.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, that specializes in discovering and developing targeted therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which integrates genome-wide analysis and CRISPR technology, Repare systematically identifies and advances cancer therapies aimed at genomic instability, particularly in DNA damage repair. The company's lead candidate, RP-3500, is an oral small molecule inhibitor designed for solid tumors with specific genomic alterations related to DNA damage repair. In addition, Repare is developing innovative programs such as a CCNE1-SL inhibitor for tumors with CCNE1 amplification and a Polymerase Theta program targeting BRCA mutations and other genomic changes. Founded in 2016, Repare Therapeutics is focused on addressing the unique vulnerabilities of tumor cells in genetically defined patient populations to enhance cancer treatment outcomes.

Dragonfly Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, founded in 2015. The company specializes in developing innovative therapeutics that stimulate immune responses against cancer, utilizing its proprietary TriNKET platform. Dragonfly's approach focuses on harnessing the power of natural killer cells and other components of the innate immune system to counteract the immune suppressive factors found in the tumor microenvironment. Its drug candidates are designed to be effective both as standalone treatments and in combination with existing cancer immunotherapies. The company has established strategic collaborations with major pharmaceutical firms, including Celgene Corporation and Merck, to further advance its therapeutic offerings. Dragonfly Therapeutics aims to provide breakthrough cancer treatments, informed by the expertise of its scientific founders, who are recognized leaders in cancer biology and immunology.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

Delinia, Inc. is a biotechnology company based in San Francisco, California, founded to develop innovative therapeutics targeting autoimmune and inflammatory diseases. The company's primary focus is on a molecule designed to selectively potentiate and expand regulatory T cells (Tregs), which play a vital role in maintaining immune system homeostasis and self-tolerance. Delinia's lead program aims to enhance the function of these powerful immune cells, providing potential new treatment avenues for patients suffering from autoimmune conditions. Since its incorporation in 2014, Delinia has been guided by a team of scientific founders and experienced executives dedicated to advancing its therapeutic programs into clinical development.

Anokion is a biotechnology company focused on antigen-specific immune tolerance to reduce immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. A spin-off from EPFL, it uses a platform technology that can be applied to many proteins across multiple clinical indications, including autoimmune conditions such as celiac disease, multiple sclerosis, and diabetes. The company is based in Ecublens, Switzerland.

Acetylon Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on developing small molecule drugs that target epigenetic mechanisms to enhance therapeutic outcomes in cancer and other serious diseases. Founded in 2008, Acetylon specializes in creating selective inhibitors of histone deacetylase (HDAC), utilizing its proprietary drug discovery platform to develop a portfolio of optimized compounds for oral administration. The company's lead drug candidates, ACY-1215 and ACY-241, are selective HDAC6 inhibitors currently undergoing clinical trials for the treatment of multiple myeloma. Acetylon aims to leverage its expertise in epigenetic regulation to address critical unmet medical needs in oncology and beyond.

EngMab AG is a biotechnology company founded in 2013 and headquartered in Pfaffikon, Switzerland. The company specializes in the development of engineered monoclonal antibodies aimed at enhancing immune responses against tumors. EngMab focuses on creating T-cell bispecific antibodies that target specific tumor antigens, addressing significant unmet medical needs in both hematological malignancies and solid tumors. The company is engaged in extensive research and development to advance its innovative therapeutic solutions. Although it operates independently, EngMab is backed by private Swiss investors and was previously a subsidiary of Celgene Corporation.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Sapience Therapeutics, Inc. is a biotechnology company focused on discovering and developing peptide-based therapeutics aimed at addressing high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company is advancing novel therapies to meet significant unmet medical needs. Its lead product, ST101, is an inhibitor of the transcription factor C/EBPß, which is overexpressed in various cancers and plays a critical role in cellular differentiation, tumor survival, and proliferation. ST101 reduces the expression of several target genes and proteins associated with cancer cell survival and growth, inducing selective cytotoxicity in tumor types such as breast cancer, melanoma, prostate cancer, glioblastoma multiforme, lung cancer, and acute myeloid leukemia. The company aims to develop first-in-class treatments for deadly conditions, with a particular focus on glioblastoma, the most aggressive form of brain cancer.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Agenovir Corporation is dedicated to the research and development of antiviral therapeutics aimed at addressing diseases linked to latent or persistent viral reservoirs. Founded in 2014 and headquartered in South San Francisco, California, the company specializes in innovative nucleases, including CRISPR/Cas9 technology, to disrupt viral DNA. This approach enables the development of a new class of therapeutics designed to eliminate pathogenic viral genomes, thereby providing healthcare providers with effective treatment options for patients suffering from chronic viral infections. Agenovir operates as a subsidiary of Vir Biotechnology, Inc. as of January 31, 2019.

IDEAYA Biosciences, Inc., established in 2015 and headquartered in South San Francisco, California, specializes in oncology-focused precision medicine. The company discovers and develops targeted therapeutics for patient populations selected through molecular diagnostics. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently in Phase 1/2 clinical trials for genetically-defined cancers with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting MAT2A, Pol-theta, PARG, and WRN in various solid tumors. The company collaborates with institutions like Cancer Research UK and Pfizer Inc., and has partnerships with industry leaders such as GlaxoSmithKline plc.

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally delivered small-molecule therapies for oncology and inflammatory diseases. It uses a proprietary discovery and development engine to create highly selective compounds that modulate immune responses. The company's lead oncology candidate, FLX475, targets the C-C motif chemokine receptor 4 and is in a Phase 1/2 program as monotherapy and in combination with pembrolizumab. The lead inflammation candidate, RPT193, is designed to selectively inhibit migration of type 2 T helper cells into inflamed tissues. Additional targets such as general control nonderepressible 2 and hematopoietic progenitor kinase 1 are in discovery. Founded in 2015 and headquartered in South San Francisco, the company aims to address unmet medical needs in cancer and inflammatory diseases.

Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

Aitia is a leader in the application of Causal AI and Digital Twins focused on advancing drug discovery and development. The company utilizes machine learning and the convergence of multi-omic patient data to create Digital Twins that replicate the biological mechanisms of diseases. This innovative approach is particularly impactful in areas such as oncology, neurodegenerative disorders, and immunology. Aitia's Gemini Digital Twins are currently employed to identify novel therapies and expedite research and development in various conditions, including multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with additional projects underway. The company collaborates with several prominent pharmaceutical firms, academic institutions, medical societies, and patient advocacy groups worldwide, thereby enhancing the potential for breakthroughs in medicine.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Receptos, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the discovery and development of therapeutics for immune disorders. The company’s lead product, ozanimod, is an oral therapy currently undergoing phase III trials for relapsing multiple sclerosis and phase II studies for ulcerative colitis and Crohn's disease. Additionally, Receptos is developing RPC4046, a monoclonal antibody in phase II trials for eosinophilic esophagitis, an immune-mediated condition. The company is also conducting preclinical research on glucagon-like peptide-1 receptor small molecule positive allosteric modulators for the treatment of Type 2 diabetes. Receptos was founded in 2008 and was formerly known as Receptor Pharmaceuticals, Inc. It became a subsidiary of Celgene Corporation in 2015.

Lycera is a preclinical-stage biopharmaceutical company dedicated to developing small molecule immunomodulators aimed at treating autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company focuses on creating first-in-class drugs that leverage proprietary technology platforms, including small molecules that modulate a target central to cellular bioenergetics and molecules that target the Th17 pathway. By utilizing ATPase modulators, Lycera’s drug candidates are designed to offer oral efficacy while minimizing the adverse effects associated with conventional antiproliferative and immunosuppressive treatments. Through its innovative approach, Lycera aims to provide effective therapeutic options for patients suffering from various immune-related conditions.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

Quanticel Pharmaceuticals is a privately held drug discovery company focused on developing innovative treatments for cancer and other life-threatening diseases. The company utilizes its proprietary platform for single-cell genomic analysis, which allows for the identification and discovery of first-in-class oncology therapeutics. By leveraging advanced genomic techniques, Quanticel aims to create breakthrough medicines that address unmet medical needs in cancer treatment.

Flexus Biosciences, established in 2013 and based in San Carlos, California, is a privately-held biopharmaceutical company dedicated to developing innovative small-molecule cancer therapeutics. Its primary focus lies in targeting regulatory T cells, aiming to create novel immunotherapies that enhance the body's immune response against cancer.

Sequenta is a biotechnology company focused on the development of clinical diagnostics that leverage innovative methods to assess immune system status. Founded in 2008 by previous entrepreneurs from ParaAllele BioScience, Sequenta employs advanced techniques to analyze the immune cell receptor genes, which exhibit significant variability in the human genome. This diversity is critical for understanding various health conditions and diseases, enabling Sequenta to provide insights that may influence numerous clinical decisions through a single, powerful assay. The company's approach capitalizes on the reduced costs of DNA sequencing, positioning Sequenta at the forefront of advancements in immune-related diagnostics.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

Acetylon Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on developing small molecule drugs that target epigenetic mechanisms to enhance therapeutic outcomes in cancer and other serious diseases. Founded in 2008, Acetylon specializes in creating selective inhibitors of histone deacetylase (HDAC), utilizing its proprietary drug discovery platform to develop a portfolio of optimized compounds for oral administration. The company's lead drug candidates, ACY-1215 and ACY-241, are selective HDAC6 inhibitors currently undergoing clinical trials for the treatment of multiple myeloma. Acetylon aims to leverage its expertise in epigenetic regulation to address critical unmet medical needs in oncology and beyond.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Acetylon Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on developing small molecule drugs that target epigenetic mechanisms to enhance therapeutic outcomes in cancer and other serious diseases. Founded in 2008, Acetylon specializes in creating selective inhibitors of histone deacetylase (HDAC), utilizing its proprietary drug discovery platform to develop a portfolio of optimized compounds for oral administration. The company's lead drug candidates, ACY-1215 and ACY-241, are selective HDAC6 inhibitors currently undergoing clinical trials for the treatment of multiple myeloma. Acetylon aims to leverage its expertise in epigenetic regulation to address critical unmet medical needs in oncology and beyond.

Avila Therapeutics is a biotechnology company based in Waltham, Massachusetts, focused on the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. The company is known for its small molecule hepatitis C virus protease inhibitor, AVL-181. Established in 2006, Avila Therapeutics has formed a strategic alliance with Sanofi-Aventis to enhance its research and development efforts. As of 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation, continuing its commitment to advancing innovative therapeutic solutions.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative treatments for cancer and rare genetic disorders related to cellular metabolism. The company specializes in small-molecule medicines targeting metabolic pathways, particularly in the context of hematologic malignancies, solid tumors, and genetic diseases. Agios offers TIBSOVO, an oral inhibitor for relapsed or refractory acute myeloid leukemia (AML), and IDHIFA, which targets AML patients with specific genetic mutations. Both drugs are undergoing various stages of clinical trials for broader applications, including frontline AML and cholangiocarcinoma. The company is also advancing other therapeutic candidates, such as mitapivat for pyruvate kinase deficiency, vorasidenib for solid tumors, and AG-270 for specific cancer types. Agios Pharmaceuticals employs a precision medicine approach to its research, aiming to identify genetically defined patient populations to enhance the efficacy of its treatments.

Abraxis BioScience, Inc. is a biotechnology company that specializes in the discovery, development, and delivery of advanced therapeutics and core technologies aimed at treating cancer and other critical illnesses. The company is known for its flagship product, Abraxane, a nanoparticle chemotherapeutic compound utilizing proprietary tumor-targeting technology for the treatment of metastatic breast cancer. In addition to Abraxane, Abraxis BioScience's portfolio includes several clinical product candidates, such as ABI-008, a solvent-free form of docetaxel for hormone refractory prostate and metastatic breast cancer; ABI-009, an mTOR inhibitor for solid tumors; ABI-010, a polyketide inhibitor targeting heat shock protein 90; ABI-011, a thiocolchicine dimer for disrupting cancer cell processes; and Coroxane, aimed at coronary and peripheral artery restenosis. The company has established strategic partnerships with various pharmaceutical firms to enhance its research and development efforts. Founded in Los Angeles, California, Abraxis BioScience was previously known as New Abraxis, Inc. and underwent a name change in November 2007. In 2010, it was acquired by a larger pharmaceutical company.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative treatments for cancer and rare genetic disorders related to cellular metabolism. The company specializes in small-molecule medicines targeting metabolic pathways, particularly in the context of hematologic malignancies, solid tumors, and genetic diseases. Agios offers TIBSOVO, an oral inhibitor for relapsed or refractory acute myeloid leukemia (AML), and IDHIFA, which targets AML patients with specific genetic mutations. Both drugs are undergoing various stages of clinical trials for broader applications, including frontline AML and cholangiocarcinoma. The company is also advancing other therapeutic candidates, such as mitapivat for pyruvate kinase deficiency, vorasidenib for solid tumors, and AG-270 for specific cancer types. Agios Pharmaceuticals employs a precision medicine approach to its research, aiming to identify genetically defined patient populations to enhance the efficacy of its treatments.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing and advancing clinical-stage oncology drug candidates. Owned by Celgene, the company specializes in hematological malignancies and is best known for its lead compound, romidepsin. This late-stage oncology drug is a histone deacetylase (HDAC) inhibitor that has demonstrated potential efficacy in treating various forms of T-cell lymphomas and other hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester Pharmaceuticals retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of multiple HDAC classes in preclinical studies. The company aims to progress its drug candidates through regulatory approval and commercialization to address unmet medical needs in oncology.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Signal Pharmaceuticals is a California-based biopharmaceutical company founded by David Anderson, Alan Lewis, Mark Carmen, and Jackie Johnson. The company focuses on the research and development of small-molecule drugs aimed at regulating gene expression associated with various diseases. In 2009, Signal Pharmaceuticals was acquired by Celgene, expanding its capabilities and resources in the biopharmaceutical sector.